Xiaomei Li

Xiaomei Li specializes in PE/VC, capital markets and M&A. She has extensive experience in PE/VC financing and has been in charge of numerous projects of great influence, covering industries such as life science and healthcare, AI, high-tech, intelligent manufacturing, new materials, clean energy, TMT, education, film and media, culture and entertainment, retail, finance, and human resources.

She has advised on numerous iconic projects, including investment deals representing prestigious private investment funds and institutions such as LYFE Capital, BioTrack Capital, CCB International, Shunwei Capital, Grand Flight Investment, Qiming Venture Partners, Huaxing Healthcare Fund, HJ Partners, Kaitai Capital, Source Code Capital, Matrix, Linear Capital, Qingsong Fund, Poly Capital, Phoenix Tree Capital, JD Group, and Legend. Her experience also includes advising on multiple capital markets projects such as MicroPort EP's listing on the STAR Market, JD.com's secondary listing in Hong Kong, as well as Hong Kong IPOs forJD Health, Maoyan Entertainment, China Renaissance, and Zhaogang. Com, and Nasdaq IPOs for Sogou and Burning Rock Biotech respectively.

Ms. Li has been rated by: Chambers and Partners as a Leading Individual in Private Equity and Venture Capital in the Greater China Region Guide (2023-2026); The Legal 500 Asia Pacific Greater China as a Key Lawyer listed in the Private Equity category (2021-2026) and the Life Sciences and Healthcare category (2023-2026); IFLR1000 as a Highly Regarded individual in Private Equity (2022-2025); and rated as one of the China Lawyers of the Year 2022 (Special recommendation top 15 - High-tech & AI) by LEGALBAND.